Pharmaceutical Executive October 21, 2021

FDA is expanding its Emerging Technology Program (ETP) and providing more support for new drug applications (NDAs) that present advanced manufacturing technologies, but the agency and industry face key challenges in advancing these initiatives.

In its ongoing campaign to encourage industry adoption of more efficient and reliable pharmaceutical production methods, FDA is expanding its Emerging Technology Program (ETP) and providing more support for new drug applications (NDAs) that present advanced manufacturing technologies. While these initiatives aim to limit drug shortages and recalls due to quality issues, the program also seeks to expand investment in domestic production to enhance access to critical therapies and vaccines for U.S. patients. At the same time, the agency is collaborating with foreign regulatory authorities to...

Today's Sponsors

Qure4u
HLTH
ZeOmega

Today's Sponsors

Premier
TripleTree

Today's Sponsor

Transcarent

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
10 pharma companies working with FDA, NIH to find treatments for rare diseases
Drug barcode guru and gadfly talks FDA rules and IV robotics
FDA announces plans to regulate certain diagnostic imaging agents as devices, not drugs
FDA: 43 new drug shortages, 86 ongoing shortages in 2020
Biden's First 100 Days in Healthcare: Handling the COVID-19 Pandemic, Prospects for Drug Pricing Reform, and the Notable Lack of an FDA Commissioner